TABLE 2.

Patient Characteristics Separated by Those Patients Who Achieved Objective Response and No Objective Response on Treatment With Pembrolizumab

Patient ID	No Objective Response		Objective Response
	Count	Mean	Count	Mean
Clinical characteristics
Age (years)		42		50
Gender F/M	0/2		1/2
Ethnicity	White: 2		White: 3
Overall survival (months)		7		14
Status Alive/Dead	0/2		3/0
Stage
AJCC classification	M1c: 2		M1a: 1, M1c: 2
LDH UI/L		404		181
Treatment
Drug	Pembrolizumab: 2		Pembrolizumab: 3
Baseline FLT-PET
Uptake
SUV max		6.8		7.8
SUV peak		5.7		6.1
SUV mean		4		3.6
SUV SD		0.8		0.8
Tumor Burden
TLP		351.1		115.1
PTV		97.4		30.8
SLR		0.6		0.4
BLR		0.9		1.3
FLT-PET at 6 weeks
Uptake
Delta-SUV max		1.1		−0.5
Delta-SUV peak		1.4		−0.5
Delta-SUV mean		0.9		−0.4
Delta-SD		−0.1		−0.6
Tumor Burden
Delta-TLP		44.2		−0.7
Delta-PTV		14.6		−0.6
Delta-SLR		−0.1		0.1
Delta-BLR		0.2		0.1